SAN FRANCISCO, CA–(Marketwired – September 15, 2016) – The Australian government has bolstered Regeneus Ltd. (ASX: RGS), a regenerative medicine company targeting cancer, osteoarthritis and other musculoskeletal conditions, with $2.73 million in funding.
Included in this article is: Regeneus Ltd.
In a Sept. 12 press release, Regeneus Ltd. reported that monies received from the Research and Development (R&D) Tax Incentive Program will cover eligible R&D “activities conducted during the financial year 2016,” which “increased to 77% compared to 68% in prior financial year.” The company expects to receive similar incentives from the government agency in 2017.
Analyst Dennis Hulme of Edison Investment Research, in a report from mid-August, noted that the company is focused on “developing and commercialising its adipose-derived mesenchymal stem cell technology for musculoskeletal conditions in animals and humans.” Two candidates are in Phase 1, according to the company: Progenza, an allogeneic off-the-shelf adipose stem cell therapy to treat osteoarthritis and other musculoskeletal conditions, and RGSH4K, a human autologous personalized therapeutic cancer vaccine targeting a variety of cancers. “Cancer immunotherapy, including cancer vaccines such as RGSH4K, is a biotech hotspot.” Hulme wrote.
Continue reading this article: Regeneus Secures Government Funding for R&D
About Streetwise Reports – The Life Sciences Report
Investors rely on The Life Sciences Report to share investment ideas for the biotech, pharmaceutical, medical device, and diagnostics industries. The information provided above is for informational purposes only and is not a recommendation to buy or sell any security.
DISCLOSURE:
The following companies mentioned in the article are sponsors of Streetwise Reports: Regeneus Ltd. The companies mentioned in this article were not involved in any aspect of the article preparation. Streetwise Reports does not accept stock in exchange for its services. The information provided above is for informational purposes only and is not a recommendation to buy or sell any security.
Please see the end of the article for the complete disclosure: Regeneus Secures Government Funding for R&D
Contact Information:
Jim Patrick
publisher
Email contact